MDS Awareness Day
Wednesday 25th October marks MDS Awareness Day when the global community of patients, patient groups, healthcare professionals and pharmaceutical industry join together to support those living with myelodysplastic syndromes (MDS).
Janssen Oncology supports this global community effort and continue our commitment to make significant advances in the management of this rare condition. We intend to partner closely with academia and patient groups to further our understanding of MDS and develop new therapies.
Dr Cathy Taylor, European Therapy Area Lead, Haematology at Janssen EMEA said: “MDS remains one of the few haematological malignancies where progress has been slow. We are committed to continuing to drive innovation, together with our partners, that will hopefully improve and extend the lives of patients suffering from MDS.”
Approximately 87,000 people are newly diagnosed with MDS each year across the globe.[i] In Europe, this type of rare blood cancer affects 40-50 in every 100,000 people aged 70 years or older and the median overall survival is 15-30 months.[ii]
References
[i]The MDS Beacon. Who is at Risk? Available at: http://www.mdsbeacon.com/resources/2009/05/01/who-is-at-risk/ Last access October 2017
[ii]Fenaux P, Haase D, Sanz GF, et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl.3):iii57-iii69